Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regulus Therapeutics (RGLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,976
  • Shares Outstanding, K 8,730
  • Annual Sales, $ 70 K
  • Annual Income, $ -71,910 K
  • 36-Month Beta 1.38
  • Price/Sales 224.30
  • Price/Cash Flow N/A
  • Price/Book 1.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -1.56
  • Number of Estimates 2
  • High Estimate -1.08
  • Low Estimate -2.04
  • Prior Year -2.16
  • Growth Rate Est. (year over year) +27.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.81 +50.10%
on 10/22/18
3.14 -13.48%
on 10/23/18
+0.20 (+7.81%)
since 09/21/18
3-Month
1.81 +50.10%
on 10/22/18
4.08 -33.41%
on 08/23/18
-0.70 (-20.56%)
since 07/23/18
52-Week
1.81 +50.10%
on 10/22/18
17.28 -84.28%
on 01/18/18
-11.62 (-81.05%)
since 10/23/17

Most Recent Stories

More News
Traders Get Bullish on Shares of Regulus Therapeu, Shares Up 36.6% (RGLS)

Regulus Therapeu (NASDAQ:RGLS) is one of today's best performing low-priced stocks, up 36.6% to $2.50 on 2.5x average daily volume. Thus far today, Regulus Therapeu has traded 1.3 million shares, vs....

RGLS : 2.65 (+44.81%)
Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present preclinical...

RGLS : 2.65 (+44.81%)
Regulus Regains Compliance with NASDAQ Listing Requirements

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it received notice from...

RGLS : 2.65 (+44.81%)
Research Report Identifies Oxford Immunotec Global, Ascena Retail Group, Groupon, Epizyme, Regulus Therapeutics, and B Communications with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oxford Immunotec Global PLC...

BCOM : 9.00 (-0.55%)
OXFD : 16.28 (+0.18%)
GRPN : 3.16 (-2.77%)
RGLS : 2.65 (+44.81%)
ASNA : 3.59 (-4.77%)
EPZM : 8.31 (+0.36%)
Regulus Therapeutics Announces Reverse Stock Split

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that at the special meeting of...

RGLS : 2.65 (+44.81%)
Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan, President and...

RGLS : 2.65 (+44.81%)
Regulus Provides Pipeline Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today provided an update on advancements to its...

RGLS : 2.65 (+44.81%)
These Biotech Stocks Are Moving Higher in August

CORAL GABLES, FL / ACCESSWIRE / August 23, 2018 / and over 90% of the S&P 500 stocks have reported results. Earnings of these companies are up by more than 25% compared to the same period last year on...

OBLN : 1.87 (-1.58%)
RGLS : 2.65 (+44.81%)
Factors of Influence in 2018, Key Indicators and Opportunity within Ciena, Corium International, Regulus Therapeutics, Marten Transport, Pandora Media, and Heartland Express -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ciena Corporation (NYSE:CIEN),...

CIEN : 30.72 (-0.78%)
P : 8.68 (+0.93%)
HTLD : 18.45 (-2.59%)
RGLS : 2.65 (+44.81%)
MRTN : 18.99 (-1.96%)
CORI : 12.56 (unch)
Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of 18.75% and -10.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

RGLS : 2.65 (+44.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade RGLS with:

Business Summary

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and...

See More

Key Turning Points

2nd Resistance Point 2.07
1st Resistance Point 1.95
Last Price 2.65
1st Support Level 1.76
2nd Support Level 1.69

See More

52-Week High 17.28
Fibonacci 61.8% 11.37
Fibonacci 50% 9.55
Fibonacci 38.2% 7.72
Last Price 2.65
52-Week Low 1.81

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar